Lecanemab is approved to treat early Alzheimer disease, or mild cognitive impairment or dementia. January 31, 2024. Joszt L. FDA approves lecanemab to treat early Alzheimer disease. Joszt L. Alzheimer disease drug lecanemab successfully reduces cognitive, functional decline. FDA declines to give accelerated approval to donanemab in early symptomatic Alzheimer disease.

Source: New York Times January 31, 2024 22:44 UTC